Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 3:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Patient Safety Clear all
Completed Not applicable Interventional

Pharmacokinetics, Pharmacodynamics and Safety of Basis in Acute Kidney Injury Study

NCT03176628
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Basis, Placebo
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Jun 10, 2026, 3:47 AM EDT
Terminated Phase 3 Interventional Results available

A Study of PRN1008 in Patients With Pemphigus

NCT03762265
View directory record Official record
Conditions
Pemphigus
Interventions
Rilzabrutinib, Placebo
Drug
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Boca Raton, Florida • Coral Gables, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Jun 10, 2026, 3:47 AM EDT
Completed Phase 1 Interventional

APG-115 in Patients With Advanced Solid Tumors or Lymphomas

NCT02935907
View directory record Official record
Conditions
Patients With Advanced Solid Tumor or Lymphoma
Interventions
APG-115
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Grand Rapids, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jun 10, 2026, 3:47 AM EDT
Recruiting Phase 3 Interventional

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

NCT07197944
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Glepaglutide, Placebo
Drug · Other
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
St Louis, Missouri • Omaha, Nebraska • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 10, 2026, 3:47 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.

NCT04324021
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Emapalumab, Anakinra
Biological
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Saint Paul, Minnesota • Ridgewood, New Jersey • Flushing, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Jun 10, 2026, 3:47 AM EDT
Terminated Phase 1 Interventional

Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

NCT00137865
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
EGEN-001 (phIL-12-005/PPC)
Genetic
Lead sponsor
EGEN, Inc.
Industry
Eligibility
19 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Jun 10, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

NCT00809965
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
Interventions
Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Placebo, Standard of care
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
15,526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
73
States / cities
Birmingham, Alabama • Geneva, Alabama • Mobile, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Jun 10, 2026, 3:47 AM EDT
Terminated Phase 2 Interventional Results available

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

NCT02855164
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Tropifexor (LJN452), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
31
States / cities
Madison, Alabama • North Little Rock, Arkansas • Coronado, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jun 10, 2026, 3:47 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT05039099
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AP-101, Placebo
Drug
Lead sponsor
AL-S Pharma
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jun 10, 2026, 3:47 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin

NCT00353587
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
MBX-102, Placebo, Actos
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
18
States / cities
Jonesboro, Arkansas • Buena Park, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jun 10, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

NCT01553747
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
232
States / cities
Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Jun 10, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)

NCT00658619
View directory record Official record
Conditions
Macular Degeneration
Interventions
400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant, Sham (no implant)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Jun 10, 2026, 3:47 AM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT03802630
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jun 10, 2026, 3:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

NCT06598007
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
CT3001, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Drug
Lead sponsor
Crossignal Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

NCT01225211
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lumacaftor, Ivacaftor, Lumacaftor Placebo, Ivacaftor Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Anchorage, Alaska • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Jun 10, 2026, 3:47 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression

NCT00771134
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lu AA39959, Placebo, Quetiapine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Jun 10, 2026, 3:47 AM EDT
Recruiting Not applicable Interventional

Safety, Tolerability, and Efficacy of Enteral Nutrition Versus Standard of Care Nutrition in Hematopoietic Stem Cell Transplant Patients: A Pilot Study

NCT06004063
View directory record Official record
Conditions
Stem Cell
Interventions
Enteral nutrition (EN), Standard care parenteral nutrition (PN)
Dietary Supplement · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jun 10, 2026, 3:47 AM EDT
Active, not recruiting Phase 1 Interventional

Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer

NCT05166616
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Biopsy, Osimertinib, Triptolide Analog
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jun 10, 2026, 3:47 AM EDT
Completed Phase 1 Interventional

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

NCT03507452
View directory record Official record
Conditions
Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma, Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma, Advanced Recurrent Serous Ovarian Cancer, Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)
Interventions
BAY2287411
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Bethesda, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2023 · Synced Jun 10, 2026, 3:47 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy

NCT03508947
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
WVE-210201, Placebo
Drug
Lead sponsor
Wave Life Sciences USA, Inc.
Industry
Eligibility
5 Years to 18 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Jun 10, 2026, 3:47 AM EDT
Terminated Phase 1Phase 2 Interventional

TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension

NCT00899977
View directory record Official record
Conditions
Refractory Hypertension
Interventions
Placebo, TC-5214
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Jun 10, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available

Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

NCT03532295
View directory record Official record
Conditions
Glioma, Glioblastoma
Interventions
Epacadostat, Bevacizumab, Radiation therapy, Retifanlimab
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Phoenix, Arizona • Rochester, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jun 10, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma

NCT00579501
View directory record Official record
Conditions
Liposarcoma,Myxoid
Interventions
Trabectedin, Dexamethasone
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Coeur d'Alene, Idaho • Park Ridge, Illinois • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Jun 10, 2026, 3:47 AM EDT
Completed No phase listed Observational

Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201

NCT02956330
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Not listed
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Jun 10, 2026, 3:47 AM EDT